Vertex reports more positive telaprevir data; Zyngenia, iPierian score new venture funds

@FierceBiotech: Actavis eyes fast-growing biosimilar market. News | Follow @FierceBiotech

 @JohnCFierce:  Biovail, Valeant plan to cut 25% of combined staffs. Get the impression from Reuters that R&D is getting downplayed. Article | Follow @JohnCFierce 

> Vertex has added yet another solid block of late-stage data to support its application for the hepatitis C treatment telaprevir. Added to standard therapy, 65 percent of the treatment-resistant patients taking telaprevir were cured of hepatitis C compared to 17 percent of the standard therapy group. An NDA for the therapy is planned for the fourth quarter and analysts give it a high chance of success. Story

> The venture arms of GlaxoSmithKline and Biogen Idec have pumped up iPierian's Series B to $28 million. Google Ventures led the round in July. Report

> Gaithersburg, MD-based Zyngenia says that it raised $15 million in new venture funds from New Enterprise Associates. The money goes toward development of a pipeline of Zybodies, a group of next-gen antibodies. Release

> Forest Laboratories says an FDA panel has unanimously recommended their new antibiotic ceftaroline. A final decision is scheduled for the fourth quarter. Story

> Belgium's Galapagos has struck a deal to acquire Glaxo's Croatian R&D center, which employs 130 staffers. Report

> A federal judge has refused to lift his injunction barring federal funding of embryonic stem cell research. Story

> Plexxikon is spelling out its development methods used for PLX4032, an experimental melanoma drug the recently delivered startling results from a small human study. Story

And Finally... The drug-resistant superbug carrying the dread NDM-1 gene has popped up in Japan. Health officials plan to find out if the bug is spreading. Story

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.